Attached files
| file | filename |
|---|---|
| EX-5.1 - EX-5.1 - Passage BIO, Inc. | a2240850zex-5_1.htm |
| S-1MEF - S-1MEF - Passage BIO, Inc. | a2240850zs-1mef.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
The
Board of Directors
Passage Bio, Inc.:
We consent to the use of our report dated February 3, 2020, except for the reverse stock split described in Note 3, which is as of February 18, 2020, with respect to the balance sheets of Passage Bio, Inc. as of December 31, 2018 and 2019, and the related statements of operations, changes in convertible preferred stock and stockholders' deficit, and cash flows for the years then ended, and the related notes (collectively, the financial statements) incorporated by reference herein and to the reference to our firm under the heading "Experts" in the prospectus.
/s/ KPMG LLP
Philadelphia,
Pennsylvania
February 27, 2020
Consent of Independent Registered Public Accounting Firm